Medical Cannabis Oversight: Pennsylvania’s medical cannabis program audit found weak internal controls, inconsistent inspections, and poor complaint handling—urging standardized checklists and clearer enforcement. Local Regulation: San Francisco released draft rules for “cannabis cafes,” spelling out permit needs, security, training, and access for medical patients ahead of a Sept. 25 comment deadline. Industry & Finance: High Tide reported record Q3 2026 results, including $199M quarterly revenue and $52.7M gross profit, while Curaleaf escalated its fight with Aurora over alleged ATM-program dilution. Medical Outcomes: Minnesota’s large cancer-focused study (6,621 patients) linked medical cannabis to symptom improvements like reduced pain, nausea, vomiting, and better sleep. CBD/Topicals Product Push: Glass House Brands launched Mama Sue Professional Athlete Balm in California, positioning it as a high-potency CBD-rich topical for pain relief. Hemp/Policy Pressure: Missouri’s hemp-THC businesses brace for a ban, with federal timing changes adding uncertainty. Enforcement Abroad: UK “drug mule” cases tied to Thailand-linked cannabis more than quadrupled since 2023, with officials warning of severe penalties. Public Health & Safety: A U.S. House bill would require HHS to study how often hospitals test for marijuana and other drugs in ER overdose cases. Crackdown in Edo: Nigeria’s NDLEA destroyed five cannabis farms and seized tramadol capsules, also arresting suspects.